AUSTEDO XR ® (deutetrabenazine) extended-release tablets and AUSTEDO ® (deutetrabenazine) tablets are indicated in adults for the treatment of chorea associated with …

Once-daily AUSTEDO XR® (deutetrabenazine) extended release tablets reduce uncontrollable Tardive Dyskinesia (TD) body movements. See safety info including Boxed Warning.

1 day ago · The findings demonstrate that treatment with AUSTEDO (deutetrabenazine) tablets or AUSTEDO XR (deutetrabenazine) extended-release tablets for tardive dyskinesia (TD) led to …

2.1 Dosing Information The dose of AUSTEDO XR and AUSTEDO is determined individually for each patient based on reduction of chorea or tardive dyskinesia and tolerability. Table 1 …

Aug 20, 2025 · Austedo's drug class is a VMAT2 inhibitor (vesicular monoamine transporter 2 inhibitor). Austedo tablets are taken twice daily, and the Austedo XR (extended-release) …

3 days ago · Parkinsonism: AUSTEDO XR and AUSTEDO may cause parkinsonism in patients with Huntington’s disease or tardive dyskinesia. Parkinsonism has also been observed with …

3 days ago · Teva Pharmaceuticals presented new findings from the IMPACT-TD Registry indicating that treatment with AUSTEDO and AUSTEDO XR significantly improved the lives of …

May 29, 2024 · U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular …

Reduce involuntary movements with AUSTEDO XR® (deutetrabenazine) tablets treatment for TD. See safety info and boxed warning.

3 days ago · Teva Pharmaceutical Industries ( TEVA, Financial) has announced encouraging findings from the IMPACT-TD Registry, a real-world study assessing the efficacy of AUSTEDO …